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An arylthiazyne derivative 
is a potent inhibitor of lipid 
peroxidation and ferroptosis 
providing neuroprotection in vitro 
and in vivo
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Tarja Malm1, Jouni Sirviö2, Anu Muona2, Milla Koistinaho2, Gundars Goldsteins1 & 
Jari Koistinaho1,3*
Lipid peroxidation‑initiated ferroptosis is an iron‑dependent mechanism of programmed cell death 
taking place in neurological diseases. Here we show that a condensed benzo[b]thiazine derivative 
small molecule with an arylthiazine backbone (ADA‑409‑052) inhibits tert‑Butyl hydroperoxide 
(TBHP)‑induced lipid peroxidation (LP) and protects against ferroptotic cell death triggered by 
glutathione (GSH) depletion or glutathione peroxidase 4 (GPx4) inhibition in neuronal cell lines. In 
addition, ADA‑409‑052 suppresses pro‑inflammatory activation of BV2 microglia and protects N2a 
neuronal cells from cell death induced by pro‑inflammatory RAW 264.7 macrophages. Moreover, 
ADA‑409‑052 efficiently reduces infarct volume, edema and expression of pro‑inflammatory genes 
in a mouse model of thromboembolic stroke. Targeting ferroptosis may be a promising therapeutic 
strategy in neurological diseases involving severe neuronal death and neuroinflammation.
Abbreviations
Aif1  Allograft inflammatory factor 1
AD  Alzheimer’s disease
AA  Arachidonic acid
Arg-1  Arginase-1
CCL2  Chemokine (C–C motif) ligand 2
COX-2  Cyclooxygenase-2
DAMPs  Damage-associated molecular patterns
Fe2+/Fe3+  Free iron (ferrous/ ferric iron)
GFAP  Glial fibrillary acidic protein
GSH  Glutathione
GPx4  Glutathione peroxidase 4
iFBS  (Heat-) inactivated fetal bovine serum
iNOS  Inducible nitric oxide synthase
IFN-γ  Interferon gamma
ICH  Intracerebral hemorrhage
i.p.  Intraperitoneal
Iba1  Ionized calcium-binding adapter molecule 1
LP  Lipid peroxidation
LPS  Lipopolysaccharide
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MFI  Median of the green fluorescence intensity
MCA  Middle cerebral artery
MCP-1 (CCL2)  Monocyte chemotactic protein 1
NO  Nitric oxide
p.o.  Oral gavage/per os
PD  Parkinson’s disease
PI  Propidium iodide
PTGS2  Prostaglandin-endoperoxide synthase 2
ROS  Reactive oxygen species
RNS  Reactive nitrogen species
s.e.m.  Standard error of the mean
TE model  Thromboembolic stroke model
TBHP  tert-Butyl hydroperoxide
TLR  Toll-like receptor
TNF-α  Tumor necrosis factor alpha
tMCAO  Transient middle cerebral artery occlusion
Ferroptosis is an iron-dependent lipid peroxidation (LP) mechanism of non-apoptotic cell  death1. It was recently 
discovered to be a major cell death pathway in neurodegenerative diseases, such as Parkinson’s disease (PD), 
Alzheimer’s disease (AD), and acute brain insults, including ischemic stroke and cerebral  hemorrhage2–7. Upon 
injury, reactive oxygen species (ROS) and reactive nitrogen species (RNS) elevate free iron (Fe2+/Fe3+) concen-
tration by interacting with proteins that regulate iron storage or  release8,9. In turn,  Fe2+/Fe3+ decomposes  H2O2 
into harmful hydroxyl radicals  HO– + HO•, thereby accelerating  LP8–10.  Fe2+/Fe3+ also blocks regeneration of 
glutathione (GSH), the major cellular antioxidant. GSH is essential for the activity of the enzyme glutathione 
peroxidase 4 (GPx4) that is exclusively responsible for the reduction of cholesterol and phospholipid hydrop-
eroxides and esterified oxidized fatty  acids11–13. GSH depletion and inactivation of GPx4 are key initiators of 
 ferroptosis14. Importantly, in severe neurological diseases, such as stroke, ferroptosis is coupled to neuroin-
flammation by triggering the release of damage-associated molecular patterns (DAMPs), immunogenic lipid 
 metabolites15, and pro-inflammatory cytokines from activated immune  cells3,9,16. While the activated immune 
cells release multiple pro-inflammatory factors, they simultaneously generate ROS, initiating another route for 
 LP17,18. Thus, seemingly interdependent pathways of redox imbalance and inflammation facilitate each other and 
converge into mechanisms of neuronal damage.
Recently, two ferroptosis inhibitors, ferrostatin-1 and liproxstatin-1, were shown to be protective in mouse 
models of transient middle cerebral artery occlusion (tMCAO)19 and intracerebral hemorrhage (ICH)20. How-
ever, these two compounds poorly cross the blood–brain  barrier2,19 limiting their clinical development for brain 
diseases. Here we show that a condensed benzo[b]thiazine derivative with an arylthiazine backbone, ADA-
409-052, inhibits ferroptotic cell death of neuronal cells through suppression of LP. The compound has a low 
molecular weight (MW: 330.33 g/mol), excellent calculated lipophilicity (ClogP) of 2.31 (ideal logP value for 
passive diffusion through the blood-brain barrier is 1.5–2.721), and crosses well the blood-brain barrier in mice. 
Moreover, ADA-409-052 is strongly neuroprotective upon oral administration in a thromboembolic (TE) mouse 
model of stroke.
Results
ADA‑409‑052 prevents lipid peroxidation induced by TBHP treatment. PC-12 cells, exposed to 
1 mM tert-Butyl hydroperoxide (TBHP), yielded massive LP, as shown by the increase of C11-BODIPY green 
fluorescence signal (224.3% ± 59.1% when normalized to control, p < 0.0001, Fig. 1b). In contrast, the red fluores-
cence signal remained predominant upon simultaneous treatment with ADA-409-052 (10 µM, Fig. 1c), which was 
comparable to control conditions (media only, Fig. 1a). Already the addition of ADA-409-052 at concentrations 
as low as of 0.625 µM suppressed some LP (to 183.7% ± 47.2%; Fig. 1d). Rising concentrations of ADA-409-052 
up to 5–10 µM resulted in a potent dose-dependent reduction in TBHP-induced LP (1.25 µM: 161.12% ± 67.1%, 
2.5 µM: 129.7% ± 43.5%, 5 µM: 124.5% ± 38.8%, 10 µM: 125.0% ± 49.3%; p < 0.0001; Fig. 1d). Flow cytometry 
analysis confirmed this reduction of TBHP-induced LP by ADA-409-052, showing a significantly lower median 
fluorescent signal in TBHP-exposed (500 µM) PC-12 cells after 10 µM ADA-409-052 treatment when compared 
with vehicle (green median fluorescent intensity (MFI) of ADA-409-052 + TBHP: 9.56 ± 1.1; MFI of TBHP only: 
20.81 ± 5.3, p = 0.0006; Fig. 1e-f).
ADA‑409‑052 prevents ferroptosis induced by GPx4 inhibitor RSL3. Next, we tested ADA-
409-052′s efficacy against RSL3-induced ferroptosis in PC-12 cell cultures. The commercially available com-
pound RSL3, a class II ferroptosis inducer, inactivates GPx4 causing ferroptotic cell death. Figure  2a shows 
that 2.5 µM ADA-409-052 lowered RSL3-induced (0.25 µM) ferroptotic cell death significantly (ADA-409-052: 
36.89% ± 2.21% cell viability compared to RSL3 only: 19.8% ± 3.44%; p < 0.0001). Adding ≥ 5 µM of ADA-409-
052 rescued about ~ 100% of the RSL3-treated cell population (ADA-409-052: 5 µM: 103.21% ± 1.45%, 10 µM: 
102.39% ± 3.64%, 20 µM: 97.70% ± 1.39%; p < 0.0001). In comparison, our neuroprotective positive control com-
pound, minocycline, was inefficient at concentrations below 10 µM and remained weak also at higher concen-
trations, although reaching significance (minocycline: 10 µM: 44.36% ± 4.1% cell viability, p < 0.0001; 20 µM: 
53.87% ± 5.3% cell viability; p < 0.0001; Fig. 2b).
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ADA‑409‑052 prevents ferroptosis induced by glutathione depletion. High extracellular con-
centrations of glutamate cause GSH-depletion by inhibiting the cysteine/glutamate antiporter system  xc−22. 
This depletion inhibits GPx4-activity, thereby initiating ferroptosis. Figure  2c,d show that 20  mM glutamate 
alone resulted in over 90% death of PC-12 cells, while glutamate-exposure in combination with 5, 10, or 20 µM 
ADA-409-052 rescued more than 90% of the cells (cell survival ADA-409-052: 5 µM: 92.18% ± 4.45%, 10 µM: 
96.2% ± 3.98%, 20 µM: 91.53% ± 2.52%; p < 0.0001; Fig. 2c). In contrast, minocycline was less protective at corre-
sponding concentrations (cell survival minocycline: 10 µM: 24.86% ± 2.52%; 20 µM: 49.96% ± 5.02%; p < 0.0001, 
Fig.  2d). To demonstrate that the efficacy of ADA-409-052 is independent of endogenous GSH, we deter-
mined the intracellular GSH levels in glutamate-exposed PC-12 cells. We found that ADA-409-052 prevented 
glutamate-exposed cell death efficiently (20 mM Glu: 10.87% ± 0.57%; Glu + ADA-409-052: 95.67% ± 0.95%; 
p < 0.005; Fig. 2e). Also, the GSH levels in both glutamate only and glutamate plus ADA-409-052 co-treated cells 
were significantly reduced compared to unstimulated cells (GSH-levels of: 20 mM Glu: 37.8% ± 6.8%; ADA-409-
052: 43.4% ± 6.3%, unstimulated control cells were normalized to 100%; p < 0.0001, Fig. 2f).
ADA‑409‑052 prevents changes in mitochondrial morphology in glutamate‑exposed PC‑12 
cells. Mitochondrial fragmentation is a major morphological alteration in ferroptosis, also when induced 
by high concentrations of  glutamate23–26. We thus tested whether ADA-409-052 prevents such changes in mito-
chondrial morphology of PC-12 cells exposed to ferroptosis  stimulation23. Live cell imaging of MitoTracker Red 
CMXRos stained mitochondria showed similar morphology of control, ADA-409-052, as well as glutamate and 
ADA-409-052-co-treated cells without signs of fragmentation (Fig. 3a–c,d–g). In contrast, glutamate-exposed 
cells show clear signs of pronounced fragmentation and reduced mitochondrial density (Fig. 3d,h), comparable 
with data shown  elsewhere23,26.
ADA‑409‑052 inhibits inflammation in an in vitro model of LPS stimulation. Lipopolysaccha-
ride (LPS) stimulates inflammatory activation of microglial BV2 cells, which is associated with a redox imbal-
ance. We assessed the expression of inducible nitric oxide synthase (iNOS) by measuring the release of nitric 
oxide (NO) into the culture medium 24 h after administration of 50 ng/ml LPS. Co-administration of LPS with 
ADA-409-052 yielded a dose-dependent reduction in NO release (5 µM: 92.42% ± 4.38%; p = 0.0384; 10 µM: 
72.33% ± 6.65%, 20 µM: 60.03% ± 9.53%; p < 0.0001; Fig. 4a).
ADA‑409‑052 is neuroprotective in a co‑culture model of N2a cells and stimulated RAW 264.7 
macrophages. To determine whether ADA-409-052 protects against inflammation-mediated neuronal 
death, we exposed co-cultures of N2a cells and RAW 264.7 macrophages to 25 ng/ml LPS and 25 ng/ml inter-
feron gamma (IFN-γ) for 24 h. The exposure resulted in about 40% neuronal cell death when compared with 
vehicle treatment (LPS/IFN-γ: 60.15% ± 2.28% viability; p < 0.0001). ADA-409-052 improved N2a cell viability 
Figure 1.  ADA-409-052 treatment protects PC-12 cells from TBHP-induced LP visualized with C11-BODIPY, 
a marker for cellular and intramembrane LP. (a–c) Representative, microscopic pictures of PC-12 cells exposed 
to (a) media control, (b) 1 mM TBHP, a class IV ferroptosis inducer, or (c) TBHP and ADA-409-052 (10 µM); 
scale bar: 100 µm. (d) Quantitative analysis of LP detected by a shift in the fluorescence signal. Data normalized 
to control and displayed as percentage ± s.e.m.; n = 3; One-way ANOVA with Tukey’s multiple comparison test; 
****p < 0.0001. (e) Flow cytometry analysis of TBHP-exposed (500 µM) PC-12 cells demonstrated protection 
upon the addition of 10 µM ADA-409-052. Data are shown as the averaged green channel (488 nm laser, 530/30 
filter) median fluorescence intensity (MFI) ± s.e.m.; n = 6/5. Unpaired, two-tailed student’s t-test; ***p < 0.001. 
(f) Representative histogram showing the median of the detected green fluorescence intensity (log values) after 
TBHP treatment only (red) or TBHP and ADA-409-052 (black) using flow cytometry.
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Figure 2.  ADA-409-052 is protective against ferroptotic cell death in in vitro models of ferroptosis inducer 
class I and II. Increased cell viability, detected by the resazurin assay, illustrates the efficacy of ADA-409-052 on 
cultured PC-12 cells against either RSL3, a class II ferroptosis inducer inactivating GPx4, or glutamate, causing 
GSH depletion by inhibiting the system  xc−. (a) ADA-409-052 protects PC-12 cells against RSL3-induced 
(0.25 µM) ferroptotic cell death significantly at all given concentrations (ADA-409-052: 2.5–20 µM). (b) Low 
concentrations of minocycline (2.5 or 5 µM) were inefficient against RSL3-mediated cell death. However, 
concentrations of 10 and 20 µM significantly improved cell survival. One-way ANOVA followed by Tukey’s 
multiple comparison test; data are presented as percentage ± s.e.m.; technical n = 6; ***p < 0.0001. (c) ADA-409-
052 (5–20 µM) prevented glutamate-induced (20 mM) ferroptotic cell death almost entirely. (d) Minocycline 
was only protective at concentrations of 10 and 20 µM. One-way ANOVA followed by Tukey’s multiple 
comparison test; data are presented as percentage ± s.e.m.; technical n = 6; ***p < 0.0001. (e,f) Glutamate-
induced reduction of intracellular GSH-levels remains unchanged by ADA-409-052. Exposure of PC-12 cells 
to glutamate (20 mM) caused a major reduction of cell viability (f) and GSH levels (e) when compared with 
untreated control cells. While the cell viability was rescued almost entirely by the addition of ADA-409-052 
(5 µM), the GSH levels remained comparable to glutamate-exposed cells. One-way ANOVA followed by Tukey’s 
multiple comparison test; data are presented as percentage ± s.e.m.; technical n = 6; **p = 0.0013; #p < 0.0001.
5
Vol.:(0123456789)
Scientific Reports |         (2021) 11:3518  | https://doi.org/10.1038/s41598-021-81741-3
www.nature.com/scientificreports/
significantly (5 µM ADA-409-052: 64.78% ± 1.77%; p = 0.0341), whereas minocycline failed to increase cell sur-
vival at the same concentration (5 µM minocycline: 61.32% ± 3.34% cell viability; p = 0.61; all Fig. 4b).
ADA‑409‑052 modulates the cytokine secretion of LPS‑stimulated BV2 microglial cells 
in vitro. By using the CBA mouse inflammation kit, we determined the effect of ADA-409-052 on the secre-
tion of pro- and anti-inflammatory cytokines from BV2 cells. The secretion of the anti-inflammatory IL-10 
remained unaltered by all used concentrations of ADA-409-052 of BV2 cells (Fig. 4c). However, the addition of 
10 µM of the compound reduced the baseline (0 µM ADA-409-052) secretion of MCP-1 by BV2 cells signifi-
cantly (0 µM ADA-409-052: 100% ± 7.43%, 10 µM ADA-409-052: 73.33% ± 5.14%; p = 0.026; Fig. 4d). Further-
more, the secretion of TNF-α was significantly reduced upon exposure to 5 µM when compared with control 
condition (5 µM ADA-409-052: 69.15% ± 3.24%, p = 0.042, Fig. 4e).
Orally administered ADA‑409‑052 shows fast absorption and good brain penetration. Using 
a pharmacokinetic study in mice, we established an in vivo treatment protocol. Orally administered ADA-409-
052 at the dose of 10 mg/kg showed individual (n = 3) maximal plasma concentrations within 0.25–1 h time 
window, followed by a fast distribution and plasma clearance in a time window of 2–8 h (data not shown). At 
the 0.75 h time point after orally dosing 10 mg/kg ADA-409-052, plasma and brain concentrations (n = 3) were 
in the ranges 1080–1324 ng/ml and 1100–1526 ng/g tissue, respectively. Oral administration of 30 mg/kg ADA-
409-052 resulted in a mean plasma concentration of 3771 ng/ml and a mean brain concentration of 3237 ng/g at 
0.75 h. The concentrations dropped to 23.7 ng/ml and 30.9 ng/g at 4 h, respectively, and below detection limit at 
24 h (n = 3 per time point). These results indicated fast and linear dose-dependent oral exposures with excellent 
brain penetration with a relatively short half-life in the plasma and brain.
Oral administration of ADA‑409‑052 provided protection in the mouse model of thromboem‑
bolic stroke. Next, we evaluated whether ADA-409-52 provides neuroprotection in  vivo in a TE mouse 
model of stroke. Minocycline treatment was used as a positive control. ADA-409-052 and minocycline were 
repeatedly administered post-stroke (Fig. 5a,b). Mice treated with corresponding vehicles were included as neg-
ative controls. The oral dosing paradigm of ADA-409-052 was based on our pharmacokinetic study. We dosed 
minocycline to achieve maximal protection according previous  data27,28. Quantification of the lesion volume by 
MRI analysis 24 h post-stroke demonstrated a 50% reduction in mice treated with ADA-409-052 when com-
pared to vehicle treatment (ADA-409-052: 10.2% ± 6.1%, vehicle: 20.5% ± 6.5%; p = 0.0038; Fig. 5c). As expected, 
also minocycline reduced the lesion volume significantly when compared to its vehicle treatment (minocycline: 
10.3% ± 4.5%, vehicle: 19% ± 8.7%; p = 0.0319; Fig. 5c). In addition and importantly, ADA-409-052 attenuated 
the edematous volume by 39% (ADA-409-052: 5.6% ± 3.3%, vehicle: 9.2% ± 3.1%; p = 0.0145; Fig. 5d), whereas 
minocycline had no significant effect on brain swelling (minocycline: 5.7% ± 3.0%, vehicle: 8.5% ± 3.9%; Fig. 5d). 
Figure 3.  Changes in mitochondrial morphology in glutamate-exposed PC-12 cells are prevented by ADA-
409-052. MitoTracker Red CMXRos was used to stain mitochondria of PC-12 cells after 24 h of exposure to 
(a,e) 20 mM glutamate, (b,f) glutamate and 10 µM ADA-409-502, or (c,g) ADA-409-052 only, plus control 
(d,h; media only). (b–d,f–h) Cells, exposed to ADA-409-052 in absence or presence of glutamate show a similar 
distribution and density of MitoTracker Red CMXRos-positive structures as control cells. (a,e) However, in 
glutamate-exposed cells appear distribution and density altered, and the overall number of viable cells reduced. 
Mitochondria were detected by confocal microscopy in live cells and magnified images (e–h) were produced 
using Imaris; red boxes indicate magnifications. Scale bar: 10 µm; 2 µm for magnifications.
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Figure 4.  (a) ADA-409-052 inhibits LPS-induced inflammation in BV2 microglial-like cells. The addition of 
5, 10, and 20 µM ADA-409-052 significantly attenuated the release of NO, measured from the media of LPS-
exposed BV2 cells using the Griess reagent, when compared to cells treated with LPS only. Data are represented 
as percentages of NO-release after normalization to LPS-stimulated BV2 cells ± s.e.m.; unpaired, two-tailed 
student’s t-test; technical n = 6; *p < 0.05, ***p < 0.0001. (b) ADA-409-052 protects N2a neuronal cells when 
co-cultured with LPS-stimulated RAW 264.7 macrophages. Boxplots show that LPS and INF-γ treatment of 
co-cultured N2a cells and RAW 264.7 macrophages decreased the viability of N2a cells about 40% as detected 
by the CytoFLEX S (Beckman Coulter) as a fraction of CD11b negative  (CD11b-), PI negative  (PI-), surviving 
cells to the total number of gated cells, normalized to the control sample. Co-treatment of ADA-409-052 and 
LPS/INF-γ resulted in a significant increase of the N2a cell viability, detected by the reduced percentage of 
 CD11b-/ PI positive  (PI+, dead) cells when compared to LPS/INF-γ treatment only. In contrast, the proportion 
of  CD11b-/PI+ N2a cells remained unaltered by minocycline. Cell survival is displayed as individual boxplot per 
treatment with interquartile range, whiskers set from min to max; unpaired, two-tailed student’s t-test; technical 
n = 3/4; *p = 0.0314. (c–e) ADA-409-052 alters the expression of pro- and anti-inflammatory cytokine expression 
of BV2 microglial cells. By measuring cytokine-secretion of ADA-409-052-stimulated BV2 cells, using the BD 
CBA mouse inflammation kit, (c) no changes in secretion of the anti-inflammatory IL-10 were detected. (d) 
However, we detected a major decrease of MCP-1 upon the addition of 10 µM ADA-409-052. (e) Furthermore, 
TNF-α decreased upon ADA-409-052-stimulation (5 µM) significantly when compared with untreated cells 
(0 µM ADA-409-052). Student’s t-test, n = 4; *p < 0.05.
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Blood gas levels measured from six randomly selected mice that went through the stroke operation remained 
unaltered by ADA-409-052 treatment, methylcellulose (vehicle) respectively (data not shown).
ADA‑409‑052 decreased the expression of pro‑inflammatory genes after ischemic 
stroke. Stroke is well known to trigger inflammation that contributes to ischemic damage. Since ADA-409-
052 provided a mild protection against inflammation-induced neuronal death in vitro, we evaluated whether 
ADA-409-052 ameliorates ischemia-induced inflammation by analyzing the expression of astrocytic Gfap, 
and allograft inflammatory Aif1 encoding ionized calcium-binding adapter molecule 1 (Iba1), a commonly 
used microglia marker. Already during the phase of early acute inflammation at 24 h post-stroke, ADA-409-
052 suppressed the stroke-induced expression of Gfap in the ipsilateral peri-ischemic area (from 1.059 ± 0.397 
to 0.793 ± 0.197; p < 0.05; Fig.  6a), while the expression of Aif1 remained unchanged at the given time point 
(Fig. 6b). However, in comparison to vehicle-treated mice, ADA-409-052 decreased the mRNA expression of 
Ccl2, in the ipsilateral perilesional tissue (ADA-409-052: 6.6 ± 0.294 to vehicle: 10.05 ± 0.584; p = 0.0278; Fig. 6c). 
Furthermore, the expression of Arg1 (arginase-1) was reduced in the ipsilateral peri-ischemic area of ADA-
409-052-treated mice when compared to contralateral peri-ischemic area (ipsilateral: 0.639 ± 0.334 vs contralat-
eral: 1.288 ± 0.501; p < 0.001; Fig. 6d). Both compounds reduced the ipsilateral mRNA expression of Il6 signifi-
cantly in comparison to the contralateral expression (ADA-409-052, ipsilateral: 0.688 ± 0.425 vs contralateral: 
1.479 ± 0.396; p < 0.0003; minocycline, ipsilateral: 0.422 ± 0.232 vs contralateral: 0.762 ± 0.375; p < 0.01; Fig. 6e). 
However, expression of Il10 or Tnfα at 24 h post-stroke remained unchanged (data not shown). Interestingly, the 
expression of Hmox1, encoding for the enzyme heme oxygenase 1 that releases ferrous iron when catabolizing 
heme, was significantly reduced in the ipsilateral peri-ischemic area of ADA-409-052- and minocycline-treated 
mice compared with the corresponding contralateral expression (ADA-409-052, ipsilateral: 0.68 ± 0.33 vs. con-
tralateral: 1.17 ± 0.33; p = 0.0011; minocycline, ipsilateral: 0.68 ± 0.39 vs. contralateral: 0.96 ± 0.13; p = 0.0203; 
Figure 5.  ADA-409-052 administration had a substantial neuroprotective effect in the TE-mouse model. The 
table (a) displays the group sizes, drug dosing and administration regime. ADA-409-052 was administered every 
4 h, starting -1 h before TE-surgery, with 100 mg/kg at 10 ml/kg p.o. in conscious mice, methylcellulose was 
given accordingly. Minocycline was injected i.p. as a first dose of 60 mg/kg and a second dose of 45 mg/kg, every 
12 h, whereas 0.2 ml of saline were injected i.p. to the vehicle group. Randomization was done using QuickCalcs 
(GraphPad Software). (b) shows a schematic drawing of the MCA-anatomy in the mouse brain, a magnified 
view below displays the inserted micropipette, and the in situ clot formation of the murine α-thrombin within 
the MCA (red box indicates the magnified area). (c,d) ADA-409-052 treatment significantly reduced infarct 
volume and brain edema in mice at 24 h post-ischemic stroke. Minocycline treatment, a competitor compound 
that was used as positive control, caused a significant reduction of the lesion volume. Of note, minocycline 
failed to reduce the edema size. Lesion and edema volume were assessed using T2-weighted MRI images and 
calculated according Shuaib’ s  formula77. Values are presented as mean ± s.e.m.; unpaired, two-tailed student’s 
t-test; n = 10–15; *p < 0.05; **p < 0.005.
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Fig. 6f) and between ADA-409-052- and vehicle-treated control mice (vehicle, ipsilateral: 1.11 ± 0.44; p = 0.0212; 
Fig. 6f).
CBA-analyses of plasma samples, taken at 24 h post-stroke, using the mouse inflammation kit of the BD 
CBA, revealed significantly lower IL-6 levels in mice treated with ADA-409-052 (5.38 ± 0.354 pg/ml) when 
compared with vehicle-treated mice (8.27 ± 1.06 pg/ml, p = 0.027; Fig. 6g). Although the levels of MCP-1 and 
TNF-α appeared visibly higher in minocycline-treated mice when compared with ADA-409-052-treated mice, 
the averages remained statistically insignificant between all treatment groups (Fig. 6h,i). The gene expression 
data of Il10, however, are in line with the peripheral secretion into the blood plasma of the anti-inflammatory 
interleukin (Fig. 6j), as both remained unaltered.
Discussion
The brain is the most susceptible mammalian tissue to the oxidative stress caused by an imbalance of redox 
reactions. This is due to the brain being extremely rich in lipids with unsaturated fatty acids, which are major 
substrates for ROS production, while simultaneously consuming about 20% of the body’s  oxygen29,30. In addition, 
most brain areas have a high iron concentration, needed for iron-catalyzed processes, such as oxygen trans-
portation, oxidative phosphorylation, myelin synthesis, and neurotransmitter  metabolism31, leaving the brain 
sensitive to abnormal iron homeostasis and iron-dependent  LP32. The risk of unbalanced iron homeostasis and 
iron-dependent LP is high, especially in the elderly, as iron accumulates into the brain during  aging3,33. Moreover, 
abnormally high iron concentrations are found in affected brain areas in neurodegenerative diseases, such as AD, 
PD, amyotrophic lateral sclerosis and  stroke5,29,31,33,34. Hence, ferroptosis is considered a major form of cell death 
in neurodegenerative diseases and  stroke5, making it a potential target for therapies of age-related brain diseases.
Our study demonstrates that in neuronal cell lines ADA-409-052, a condensed benzo[b]thiazine derivative 
with an arylthiazine backbone, strongly inhibits LP and the subsequent cell death induced by GSH depletion or 
blockade of GPx4, the key-triggers of ferroptosis. Both GSH depletion and GPx4 deficiency are highly relevant 
conditions, as GPx4 catalyzes the reduction of lipid peroxides at the expense of GSH, and as levels of both GSH 
and GPx4 are reduced in stroke and neurodegenerative  diseases35. Attempts to boost GPx4 directly or indirectly 
in animal models of neurodegenerative diseases and stroke have been  successful36–38, but remained unfeasible 
and inefficient in  clinics39–41. An advantage of ADA-409-052 and molecules alike is that their ability to inhibit 
ferroptosis is independent on the availability of GSH, suggesting that ADA-409-052 could protect the brain even 
when GSH levels decrease. Furthermore, ADA-409-052 inhibited glutamate-induced changes of mitochondrial 
morphology, facilitating better cell survival.
Neuroinflammation is a well-known immune response to protect brain tissue and neurons from toxic mol-
ecules or noxious structures in all neurodegenerative diseases and acute brain insults. Still, when overwhelming 
or prolonged, it may turn harmful and promote neuronal damage and  loss42–45. An important inflammatory 
pathway is the metabolism of arachidonic acid (AA), a major component of cell membrane lipids, into precur-
sors of bioactive pro-inflammatory mediators, such as the eicosanoids, prostaglandins, interleukins, TNF and 
leukotrienes, that promote inflammatory  cascades46,47. There is a complex relationship between ferroptosis, AA 
metabolism, and pro-inflammatory mediators. Ferroptotic cell death has been reported to be enhanced by pro-
inflammatory polarization of macrophages and  microglia48. In addition, previous studies indicate that, at least in 
cancer cells, ferroptosis can have pro-inflammatory effects and initiate inflammation by increasing the expression 
of PTGS2 (which encodes cyclooxygenase-2 (COX-2)), accelerating AA metabolism and promoting the secretion 
of pro-inflammatory  molecules49–51. On the other hand, inflammatory cytokines (such as TNF, PGE2, IL-1, IL-1β, 
and IL-6) have been shown to directly alter the level and activity of GPx4 in cancer  cells52 and TNF treatment 
of cells leads to the sustained downregulation of GPx4 that may trigger  ferroptosis50. The reduced secretion of 
MCP-1 and TNF-α, measured from ADA-409-052-stimulated BV2 cells using the BD CBA mouse inflammation 
kit, further indicates that the compound improves the activity of GPx4, countervailing pro-inflammatory and 
ferroptotic conditions. To further prove the compound’s efficacy, we tested ADA-409-052 on neuronal death in 
a neuron (N2a)—macrophage (RAW 264.7) co-culture model of LPS/IFN-γ-induced neuroinflammation. Our 
Figure 6.  ADA-409-052 administration in vivo reduced the expression levels of pro-inflammatory markers 
(a–f) and altered the peripheral cytokine secretion (g–j) at 1 day post-ischemia. The mRNA expression of 
tissue samples from the ipsi- and contralateral peri-ischemic area at 24 h was analyzed using qPCR. Expression 
levels of (a) Gfap and (c) Ccl2 were markedly reduced in the ipsilateral peri-ischemic area after ADA-409-052 
treatment when compared to vehicle. (b) While, Aif1 remained unchanged throughout all groups, ADA-409-
052 lowered (d) Arg1 and (e) Il6 mRNA expression in the ipsilateral samples when compared to contralateral. 
(f) Ischemic mice treated with ADA-409-052 showed reduced Hmox1 expression in the ipsilateral peri-
ischemic area when compared to contralateral expression levels, to ipsilateral expression of vehicle-treated mice 
respectively. Minocycline decreased the expression of Hmox1 only ipsilateral when compared to contralateral. 
mRNA expression levels of peri-ischemic tissue samples from ipsi- and contralateral, data are expressed as 
mean ± s.e.m.; unpaired, two-tailed student’s t-test; n = 9–13; *p < 0.05, **p < 0.005, ***p < 0.001. (g) The secretion 
of the inflammation-mediating IL-6 was significantly reduced in ADA-409-052-treated mice when compared 
to vehicle-treated mice, as detected from the blood plasma, collected from ischemic mice at 1 dpi, by using the 
BD CBA mouse inflammation kit. (h,i) Both MCP-1 and TNF-α were equally low in ADA-409-052-treated 
mice when compared with vehicle treatment and showed a clear trend towards reduction when compared with 
minocycline-treated mice (changes did not reach significance). (j) The peripheral secretion of IL-10 remained 
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data show that ADA-409-052 suppresses pro-inflammatory activation of microglia- and macrophage-mediated 
neuronal death. Our findings are in line with previous studies showing that intracerebral injection of ferrosta-
tin-1, a ferroptosis inhibitor, reduced the expression of COX-2 with concomitant  neuroprotection20. This indi-
cates that ADA-409-052 and established ferroptosis inhibitors reduce inflammation and inflammation-induced 
injury also in brain tissue.
To investigate whether the brain penetrating compound ADA-409-052 can provide neuroprotection in vivo, 
we chose thromboembolic stroke in mice, as this model results in distinct and relatively fast brain injury and 
as it mimics the type of stroke that is very common in  clinics53,54. The model evolves a rather small, focal lesion 
ensuring a good survival rate and its mechanisms resemble those of vascular occlusion in  patients55. We also 
measured the blood flow during and after thrombin injection to secure proper and consistent clot formation, 
which we found to be reflected as very homogenous infarct volumes measured by MRI analysis, indicating the 
model’s reliability. We found that treatment with ADA-409-052 resulted in a marked neuroprotection as detected 
by significantly reduced lesion volumes post-ischemic stroke, which equaled to the reduction obtained by our 
positive control, minocycline. The protective effect of minocycline replicated in our study the results of previous 
 studies56–58. Importantly, only ADA-409-052 restricted the expansion of stroke-induced edema. This effect of 
ADA-409-052 is in line with the previous finding that intracerebral injection of a ferroptosis inhibitor reduces 
brain inflammation in a rat model of intracerebral  hemorrhage20.
Brain swelling is an important clinical measure as it is associated with deterioration and manifestation of 
neurological deficits and elevated  mortality59,60. Our data thus confirm the previous findings that ferroptosis is 
an important mechanism of both brain infarction and brain edema. Furthermore, the results suggest that ADA-
409-052, a small molecule inhibiting ferroptotic neuronal death, may be able to efficiently prevent ischemic 
neuronal death and harmful stroke-induced edema in thromboembolic stroke and prove beneficial in various 
brain diseases.
Minocycline was used as our reference compound in the stroke study as well as in key in vitro experiments. 
While we could have compared ADA-409-052 with established inhibitors of ferroptosis, we preferred the com-
pound minocycline, which is extensively characterized and tested in a large number of studies, including our 
own experiments. It is a small molecule with excellent brain penetration and proven efficacy in vivo27,58,61–67. 
Moreover, minocycline inhibits LP, attenuates iron-induced brain injury following experimental intracerebral 
 hemorrhage66,68, and results in expression of molecules counteracting the development of  ferroptosis67. It is also 
one of the most potent small molecules against experimental ischemic stroke supported by a large number of 
 studies27,69,70. Our data show that minocycline protected against ferroptotic death only at relatively high concen-
trations, which is in line with previous studies suggesting that it is not a direct ferroptosis inhibitor. Assuming 
ferroptosis is a major mechanism of stroke-induced secondary edema, it is unsurprising that ADA-409-052 and 
not minocycline significantly mitigated the brain edema that developed 24 h after ischemic insult in this study’s 
TE model of stroke.
ADA-409-052 down-regulated pro-inflammatory cytokines and chemokines induced by TE stroke as meas-
ured by qPCR, the BD CBA respectively. Among the genes with reduced expression after ADA-409-052 treatment 
was Ccl2 (MCP-1), a marker of activated pro-inflammatory microglia/macrophages and infiltrating neutrophils, 
associated with neuronal  degeneration71. Even though, ADA-409-052 was unable to change the peripheral secre-
tion of MCP-1, only minocycline caused a certain increase of MCP-1 secretion into the plasma. Importantly, 
Il6, a pro-inflammatory downstream product of toll-like receptor (TLR)72, was reduced in both gene expression 
of ischemic brain tissue and cytokine levels of blood plasma. In addition, ADA-409-052 reduced the expression 
of stroke-induced Hmox1 that encodes heme oxygenase-1, an essential enzyme for iron-dependent LP during 
ferroptotic cell  death73. These data are in line with in vitro data indicating that ADA-409-052 efficiently inhibits 
ferroptosis and associated inflammation in brain tissue.
In conclusion, small molecule inhibitors of ferroptosis such as ADA-409-052 may be potent protective com-
pounds against neurodegeneration and acute brain insults. As mechanisms of these brain diseases are complex 
and involve several detrimental signaling pathways, an advantage of ferroptosis inhibitors is their ability to reduce 
not only ferroptosis triggered by non-enzymatic LP, but also cell death mediated by enzymatic LP heavily con-
tributed by inflammation. A combination of ferroptosis inhibitors with molecules targeting still other harmful 
pathways might offer attractive therapeutic approaches for brain disorders.
Materials and methods
In vitro lipid peroxidation analysis. C11-BODIPY 581/591 (ThermoFisher Scientific, MA, USA), was 
used as a fluorescent sensor to determine TBHP-induced LP in PC-12 cells. Analyses were done by cellular 
imaging or flow cytometry, as C11-BODIPY’s fluorescence emission peak shifts from ~ 590 nm to ~ 510 nm upon 
 oxidation74.
For the fluorescent cellular imaging, PC-12 cells (ATCC, VA, USA; for all experiments see suppl. informa-
tion for cell culturing details) were pre-incubated 90 min with 5 µM C11-BODIPY. Next, cells were washed and 
exposed for 90 min to 1 mM TBHP (Sigma, MO, USA) in the presence or absence of ADA-409-052 at different 
concentrations (0.625, 1.25, 2.5, 5, and 10 µM); DMEM media served as control. Images were taken using the 10X 
magnification at a Zeiss Observer.Z1 fluorescent microscope (AxioCam MRm, Zeiss Zen Imaging Software, Zeiss, 
Germany). Using the ImageJ software (NIH, MD, USA) an appropriate threshold was set and the mean grey value 
for each channel (8-bit images) was calculated. Results are displayed as the red/green-ratio, normalized to control.
For the flow cytometry experiments, PC-12 cells were incubated with 500 µM TBHP + /- 10 µM ADA-409-052 
for 60 min. Stimulants were replaced with DMEM media containing 5 µM C11-BODIPY for 30 min, before cells 
were washed with 1X PBS containing 3% iFBS, and resuspended in 1X PBS containing 1% iFBS. Samples were 
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measured on a BD FACSCalibur (488- and 633-nm lasers, standard configuration, BD Bioscience, CA, USA). 
Data were analyzed using FCS Express v5 (DeNovo Software, CA, USA).
In vitro ferroptosis models. To test the anti-ferroptotic properties of ADA-409-052, PC-12 cells were 
exposed for 24 h to either 0.25 µM RSL3 (Selleck Chemicals, TX, USA) or 20 mM glutamate (Glu, Sigma) with 
or without ADA-409-052 at following concentrations: 2.5, 5, 10, and 20 µM. Minocycline (Sigma) was used in 
parallel at the same concentrations. The compounds’ efficacy in cell protection was measured as cell viability 24 h 
post-treatment using the resazurin assay. In brief, cells were incubated for 2 h at 37 °C with 10 µM resazurin in 
HBSS. The absorbance was measured at 485 nm. Additionally, ADA-409-052’s effect on intracellular GSH levels 
was measured. We thus exposed PC-12 cells to 20 mM glutamate with or without 5 µM ADA-409-052. After 24 h 
of exposure, GSH was extracted from the collected cell pellet with 5% sulfosalicylic acid and the supernatant 
neutralized with 3 M Tris. The Amplite Rapid Fluorimetric Glutathione GSH/GSSG Ratio Assay Kit (AAT Bio-
quest, Sunnyvale, CA, USA) was used to measure the GSH concentration according manufacturer’s instructions. 
All results were expressed as percentage of mean fluorescence from untreated control cells.
Visualization of mitochondria in an in vitro model of ferroptosis. To demonstrate the effect of 
ADA-409-052 on mitochondria changes upon ferroptosis, PC-12 cells were exposed to glutamate (20  mM) 
in presence or absence of ADA-409-052 (10  µM) for 24  h, as described before. Live cells were stained with 
MitoTracker Red CMXRos (ThermoFischer Scientific) and imaged with a 63X Achroplan objective on a Zeiss 
Laser Scanning Microscope 710 with Zen Imaging Software (Zeiss) (see suppl. information for the full protocol).
In vitro inflammation model on BV2 microglial cells. BV2 microglial cells were stimulated with pro-
inflammatory LPS. Therefore, BV2 cells were incubated with 50 ng/ml LPS (serotype O111:B4, Sigma) for 24 h 
in the presence or absence of ADA-409-052 using 2.5, 5, 10, and 20 µM. NO release was assessed using the Griess 
reaction (Promega, WI, USA). A standard curve was prepared using 0–100 μM sodium nitrite. Nitrite concen-
trations were presented as percentages of NO release after normalization to LPS-exposed BV2 cells. Cytokines 
were measured from conditioned media of LPS- + /− ADA-409-052-treated cells using the mouse inflammation 
kit of the BD CBA was performed according manufacturer’s instructions (for details see suppl. information). 
Data were acquired on a BD Accuri C6 flow cytometer, and the FCAP Array Software v3.0 was used for analyses 
(all BD Bioscience). Data were normalized to control-treated cells, set as 100%.
In vitro co‑culture model of neuroinflammation using N2a and stimulated RAW 264.7 mac‑
rophages. For co-culture experiments, mouse neuroblastoma Neuro-2a (N2a) cells were seeded in a 1:1 
ratio with RAW 264.7 macrophages and treated for 24 h with 25 ng/ml LPS and 25 ng/ml IFN-γ (Sigma) with 
or without ADA-409-052 or minocycline (both 5 µM). Next, cells were collected and incubated with CD11b-
Alexa Fluor 647 (1:200, BD Biosciences) for 30 min in the dark at 4 °C, washed with HBSS containing 3% iFBS, 
resuspended in HBSS with 1% iFBS and counterstained with propidium iodide (PI, 25 µg/ml, Sigma). Samples 
were analyzed with CytoFLEX S (Beckman Coulter, IN, USA). The surviving/dead N2a cells were detected as 
Alexa Fluor 647/CD11b negative  (CD11b-) and PI negative  (PI-/surviving), and Alexa Fluor 647/CD11b nega-
tive  (CD11b-) and PI positive  (PI+)/dead, respectively. N2a cell viability was calculated as a fraction of surviving 
cells to the total number of gated, normalized to control, presented as percentages.
In vivo experiments. Pharmacokinetics of ADA‑409‑052. Brain penetration study was carried out by 
TCG Lifesciences Ltd (Kolkata, India) in male BALB/c mice (6–8 weeks old; 18–20 g, in-house breeding). All 
procedures were in compliance with the guidelines of the Committee for Purpose of Control and Supervision of 
Experiments on Animals India and the study was approved by the Institutional Ethics Committee of Eurofins Ad-
vinus Limited (Approval No.: 019/July-2019). The experiment was carried out in compliance with the ARRIVE 
guidelines. Mice were housed individually under 12/12 h light–dark cycle with free access to food and water. In 
two experiments 10 mg/kg or 30 mg/kg of ADA-409-052 (HPLC Purity: 99.7%) dissolved in Tween-80 (0.5%, 
Merck, Germany) -methylcellulose (Sigma) solution was administered as a single bolus by oral gavage (p.o.). 
ADA-409-052- or vehicle-administered mice were sacrificed 0.75, 4, and 24 h later (n = 3/group). Heparinized 
blood samples were stored as plasma at − 80 °C. Whole-brain samples were collected and stored at − 80 °C until 
homogenization in water (1:4 = tissue:  H2O, dilution factor: 5), on ice directly prior to analysis. Bio-analysis was 
performed with API 4000 (AB Sciex Instruments, CA, USA) integrated to LC (Shimadzu, Japan) and CTC PAL 
(HTS, UT, USA) autosampler and quantified using Analyst 1.4.2 software (AB Sciex).
Thromboembolic mouse model of ischemic stroke. In accordance with the Council of Europe Leg-
islation and Regulation for Animal Protection, the National Animal Experiment Board of Finland approved 
the experiments. The experiments were carried out in compliance with the ARRIVE guidelines. Sixty C57BL/6J 
mice were randomized into four treatment groups using QuickCalcs (GraphPad Software, CA, USA): I: ADA-
409-052 (100 mg/kg in 10 ml/kg methylcellulose), II: methylcellulose (10 ml/kg, vehicle for ADA-409-052), III: 
minocycline (60 mg/kg (1st dose) or 45 mg/kg (2nd dose) in 0.2 ml saline), and IV: 0.9% NaCl (0.2 ml/kg, vehicle 
for minocycline). ADA-409-052 and methylcellulose were administered every 4 h p.o. for 24 h, starting 60 min 
before TE surgery. Minocycline and saline were injected intraperitoneal (i.p.) every 12 h (for details see Fig. 5a). 
All animals underwent TE cerebral ischemia according to Orset et al.,  200775. Briefly, 1 µl of 1 IU of α-thrombin 
(~ 2970 NIH-units/mg) was injected into the MCA-lumen (Fig. 5b). Using Laser Doppler flowmetry, proper clot 
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stabilization was ensured. Blood gases were evaluated in six ischemic mice (for a detailed protocol, see suppl. 
information).
Magnetic resonance imaging. Lesion and edema volumes were determined 24 h post-ischemia, using 
T2-weighted MRI imaging in the anaesthetized animal. MRI was performed on a vertical 9.4 T Oxford NMR 
400 magnet as described  elsewhere76. Multi-slice T2 weighted images (repetition time 3000 ms, echo time 40 ms, 
matrix 128*256, FOV 19.2 mm, 12 slices à 1 mm-thickness) were obtained. The MRI images were analyzed using 
an in-house aedes software under MATLAB environment (Math-Works, MA, USA). Lesion and edema volume 
were calculated blinded to study groups following Shuaib et al.77.
Following MRI, various samples were collected from finally anaesthetized animals (details in suppl. 
information).
Quantitative real‑time PCR analyses of mRNA levels. Total RNA was isolated from homogenized 
peri-ischemic brain tissue samples of the ipsi- and contralateral hemispheres, in TRIzol (Life technologies, CA, 
USA) according to the manufacturer’s instructions. cDNA (2.5 ng/µl) was synthesized using 500 ng of total RNA, 
dNTP, Maxima reverse transcriptase, and random hexamer primers, combined with ribonuclease inhibitors 
(ThermoFisher Scientific). The relative expression levels of mRNAs encoding the selected genes were measured. 
According manufacturer’s protocol by RT-qPCR (StepOnePlus, ThermoFisher Scientific) using specific TaqMan 
gene expression assays (ThermoFisher Scientific), the following genes were analyzed: Gfap, Arg1, Mpo, Il6, Il10, 
Tnfα, Ccl2, and Hmox1. The expression levels were normalized to b2m (beta-2 microglobulin), calculated as 
described  previously78, presented as fold change.
Analyses of peripheral cytokines in blood plasma. The mouse inflammation kit of the BD CBA 
(BD Bioscience) was used to detect cytokines secreted into the plasma of 7 mice per group at 1 dpi. CBA was 
performed according manufacturer’s instructions and data were acquired as described in suppl. information. 
Results are presented in pg/ml final concentration.
Statistical analysis. Statistical significant differences (p-values) between the means for two measurement 
groups were calculated using two-tailed distribution and two-sample equal variance of the student’s t-test; One-
way ANOVA with Tukey’s multiple comparison test was used whenever appropriate (GraphPad Prism software). 
The data are displayed as mean ± standard error of the mean (s.e.m.).
Altogether eight mice (13.34%) were excluded due to mortality, hemorrhagic transformation, or insufficient 
clot formation.
Data availability
The datasets generated and analyzed during the current study are available from the corresponding author on 
reasonable request.
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